Navigation Links
Savient Pharmaceuticals Announces Acceptance of Two Gout-Related,Abstracts for Poster Presentation at the European League Against,Rheumatism (EULAR) 2007 Annual Congress

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Jun 6, 2007 - Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that two abstracts exploring Phase 2 Puricase(R) (PEG-uricase) data and quality of life in treatment-failure gout patients will be presented at the European League Against Rheumatism (EULAR) 2007 Annual Congress taking place June 13 - 16th in Barcelona, Spain. Puricase is a PEGylated recombinant porcine urate oxidase currently in Phase 3 development for patients with treatment-failure gout.

The abstracts selected for poster presentation on Thursday, June 14 are:

-- "Pharmacokinetics and Pharmacodynamics of PEG-uricase in Patients with Hyperuricemia and Treatment-Failure Gout" (abstract #THU0358)

-- "Validation of the SF-36 and HAQ-DI in Patients with Treatment-Failure Gout" (abstract #THU0359)

The first poster presents pharmacokinetic and pharmacodynamic data from the 41-patient, 3-month duration, open-label Phase 2 trial of Puricase. The second poster presents an analysis of the application of instruments for measuring health-related quality of life and physical functioning to the assessment of patient-reported outcomes in treatment-failure gout (defined as gout patients for whom allopurinol is contraindicated or is ineffective).

In addition to the two abstracts accepted for poster presentation, two additional abstracts have been accepted for publication on-line. These are:

-- Weekly Flare Burden Index: A New Metric for Evaluating Gout Treatment (abstract # AB0748)

-- Uric Acid Lowering Therapy for Gout: Patterns of Care (abstract # AB0745)

For information about the EULAR scientific program, please visit the Congress website at www.eular.org

Savient licensed exclusive, worldwide rights to the technologies related to Puricase from Duke University ("Duke") of North Carolina and Mountain View Pharmaceuticals, Inc. ("MVP"), a California corporatio
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... evaluates the efficacy of new device for detecting polyps that ... ... Oct. 7 At the American College of,Gastroenterology Annual Scientific ... presented results from a,multi-institutional clinical study that evaluated the efficacy ...
... Results of FLEXX Trial Presented at the Osteoarthritis ... Oct. 7 Ferring Pharmaceuticals Inc.,recently presented results ... showing that EUFLEXXA(R) (1% sodium hyaluronate), a highly ... acid,(IA-HA), is superior to intra-articular saline (IA-saline) for ...
Cached Medicine Technology:National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4
(Date:7/9/2014)... the world have been linked to an emerging ... the National Institute for Mathematical and Biological Synthesis ... contribute. , In a series of mathematical ... hemorrhage of internal organs in frogs, could cause ... they are exposed to the virus every few ...
(Date:7/9/2014)... retrospective study conducted by researchers at Tufts University School ... with intellectual and developmental disabilities, the likelihood of having ... care increased. The findings, published in the July/August issue ... improve interventions designed to address the oral health of ... the dental records of 107 patients at one of ...
(Date:7/9/2014)... risen dramatically in Western societies. One frequently cited reason ... have fewer infections than previous generations, thereby delaying maturation ... at Sahlgrenska Academy, University of Gothenburg, monitored children until ... immune system in relation to allergic disease. All of ... Gtaland Region, half of them on farms that produced ...
(Date:7/8/2014)... clinicians from Plymouth, UK, and Sydney, Australia, have today ... launched ACEmobile - a free-to-use app to support the ... the first of its kind; an iPad-based tool that ... through the whole process, meaning more members of the ... of assessment. Designed by clinicians for clinicians, ACEmobile also ...
(Date:7/8/2014)... NPR/Robert Wood Johnson Foundation/Harvard School of Public Health (HSPH) ... in Americans, lives finds that about half of the ... event or experience in the past year. Nearly half ... health. , More than half of those who experienced ... say too many overall responsibilities and financial problems were ...
Breaking Medicine News(10 mins):Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:New app widens opportunities for dementia assessments 2Health News:New app widens opportunities for dementia assessments 3Health News:Poll finds health most common major stressful event in Americans' lives last year 2Health News:Poll finds health most common major stressful event in Americans' lives last year 3Health News:Poll finds health most common major stressful event in Americans' lives last year 4
... have uncovered a vital new biological clue that could ... tumour that currently kills more than 60 per cent ... Children,s Brain Tumour Research Centre, working on behalf of ... the role of the WNT biological pathway in central ...
... Children and 1,300,000 Adults Living in the U.S. with ... March 18 Senator Richard Durbin (D-IL) and Congressman ... the first time in history, will address the needs ... America,s most common birth defect that affects approximately one ...
... BOZEN, Italy, March 18 Health Robotics today announced,the ... at the,European Association of Hospital Pharmacists in Barcelona, Spain ... an updated list of the,i.v.STATION installations around the world, ... IV Robot, at the EAHP booth of,one of its ...
... Combination with a Long-Acting Interferon and Ribavirin Will ... C Virus in 2012, According to a New ... Decision Resources, one of the world,s leading research ... finds that surveyed gastroenterologists and hepatologists identify a ...
... Latino Market Underserved by other ProvidersLOS ANGELES, ... (OTC Bulletin Board: FVRL), which through its ... provides consumer-controlled Personal Health Records ("PHRs") ( ... storage solutions ( www.myesafedepositbox.com ), has entered ...
... The Dirty Secrets of Spring Cleaning Did ... actually contain chemicals to cover up the scent? Even ... home with harmful chemicals. Invite Lisa and Ron Beres ... and how to avoid them. CONTACT: Lisa and ...
Cached Medicine News:Health News:Study finds biological clue in brain tumor development 2Health News:For the First Time in U.S. History, Congress Addresses the Needs of the Congenital Heart Defect Population by Introducing the 'Congenital Heart Futures Act' 2Health News:For the First Time in U.S. History, Congress Addresses the Needs of the Congenital Heart Defect Population by Introducing the 'Congenital Heart Futures Act' 3Health News:Health Robotics Announces European Launch of i.v.STATION(TM) and Global List of 2009 Installations 2Health News:Health Robotics Announces European Launch of i.v.STATION(TM) and Global List of 2009 Installations 3Health News:Health Robotics Announces European Launch of i.v.STATION(TM) and Global List of 2009 Installations 4Health News:In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response 2Health News:In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response 3Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 2Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 3Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 4Health News:Five Hot Show Ideas for Spring-Related Topics 2
Enzyme Immunoassay of -Thromboglobulin Antigen by ELISA Method, 96 tests....
HbA1c / HbCalibrator...
Heparin-Platelet Factor 4 Induced Antibody...
Multi-constituent Calibration Plasma for Functional Assays of Coagulation Parameters on STA© Analyzers....
Medicine Products: